Recently Viewed
empty-cart

There are no Recent Items

Close
Login/Register

Close
Single User License Price USD 2,000
Single User License Price INR 135
Corporate User License Price USD 6,000
Corporate User License Price INR 405
Site License Price USD 4,000
Site License Price INR 270
Request a Quote

Report Title

Hypoparathyroidism - Pipeline Review, H1 2018

Quote Request for License Type
License Type Price  
Single User License USD 2,000
Site License USD 4,000
Enterprise Wide License USD 6,000
"Thanks for submitting the form. Our marketing team will connect back to you for the budget constraint."
Close
REQUEST A CUSTOMIZED RESEARCH

Report Title

Hypoparathyroidism - Pipeline Review, H1 2018


Quote Request for License Type
License Type Price  
Single User License USD 2,000
"Thanks for letting us know your requirement. Our research team will connect back to you for the bespoke requirement."
Close
REQUEST FOR SAMPLE REPORT

Report Title

Hypoparathyroidism - Pipeline Review, H1 2018

"Thanks for submitting the form. The concerned team will send the sample report in the next 12 hours."
"Thank you for downloading the sample report."
Close

Hypoparathyroidism - Pipeline Review, H1 2018



Executive Summary

Hypoparathyroidism - Pipeline Review, H1 2018

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoparathyroidism - Pipeline Review, H1 2018, provides an overview of the Hypoparathyroidism (Hormonal Disorders) pipeline landscape.

Hypoparathyroidism is decreased function of the parathyroid glands with underproduction of parathyroid hormone. This leads to low levels of calcium in the blood, often causing cramping and twitching of muscles (involuntary muscle contraction), and several other symptoms. The condition can be inherited, but it is also encountered after thyroid or parathyroid gland surgery, and it can be caused by immune system-related damage as well as a number of rarer causes. The treatment includes artificial form of the hormone that can be administered as replacement, calcium replacement or vitamin.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoparathyroidism - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Hypoparathyroidism (Hormonal Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoparathyroidism (Hormonal Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoparathyroidism and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I and Preclinical stages are 1, 3 and 4 respectively.

Hypoparathyroidism (Hormonal Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoparathyroidism (Hormonal Disorders).

- The pipeline guide reviews pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hypoparathyroidism (Hormonal Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hypoparathyroidism (Hormonal Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hypoparathyroidism (Hormonal Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hypoparathyroidism (Hormonal Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hypoparathyroidism (Hormonal Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Hypoparathyroidism - Overview

Hypoparathyroidism - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hypoparathyroidism - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hypoparathyroidism - Companies Involved in Therapeutics Development

Ascendis Pharma A/S

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

GC Pharma

Shire Plc

Hypoparathyroidism - Drug Profiles

ACP-014 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EB-612 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

EXT-601 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

LY-6272K - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

parathyroid hormone - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

PCO-371 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Recombinant Protein to Agonize PTHR1 for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Stem cell Therapy for Hypoparathyroidism - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hypoparathyroidism - Dormant Projects

Hypoparathyroidism - Product Development Milestones

Featured News & Press Releases

May 07, 2018: Ascendis Pharma Announces Poster Presentation on TransCon PTH Phase 1 Trial at the European Congress of Endocrinology

Apr 09, 2018: Shire's Natpar Rejects For Use Within NHS Scotland

Mar 20, 2018: New Data Presented at the Endocrine Society's 2018 Annual Meeting Advances Understanding of the Rare Disease Chronic Hypoparathyroidism

Mar 19, 2018: Ascendis Pharma Announces Posters on Rare Disease Pipeline Programs at ENDO 2018

Mar 12, 2018: Shire to Highlight Advancements in Chronic Hypoparathyroidism Research at the Endocrine Society's 2018 Annual Meeting

Jan 08, 2018: Ascendis Pharma Provides Update on Rare Disease Endocrinology Pipeline and Presents Initial Phase 1 Data for TransCon PTH

Sep 26, 2017: Ascendis Pharma Announces Dosing of Subjects in Phase 1 Trial of TransCon PTH

Sep 05, 2017: Ascendis Pharma Announces Presentations on TransCon PTH at Upcoming Medical Conferences

May 19, 2017: Shire to highlight new research into chronic hypoparathyroidism at the European Congress of Endocrinology

Apr 26, 2017: Shire Granted EU Conditional Marketing Authorisation for Natpar (Parathyroid Hormone) for the Treatment of Patients with Chronic Hypoparathyroidism

Apr 03, 2017: Ascendis Pharma Presents Data on TransCon PTH at ENDO 2017

Feb 28, 2017: Ascendis Pharma Announces Data on TransCon PTH at ENDO 2017

Feb 24, 2017: First hormone replacement therapy for parathyroid disorder

Jun 29, 2016: EnteraBio Receives Orphan Drug Approval for PTH 1-34 from European Medicines Agency

Jul 22, 2015: Entera Bio Announces Phase II Results of PTH 1-34 in Treating Hypoparathyroidism

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

To know more information on Purchase by Section, please send a mail to sales@kenresearch.com

List of Figures

Number of Products under Development for Hypoparathyroidism, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products by Targets, H1 2018

Number of Products by Stage and Targets, H1 2018

Number of Products by Mechanism of Actions, H1 2018

Number of Products by Stage and Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Molecule Types, H1 2018

Number of Products by Stage and Molecule Types, H1 2018

List of Tables

Number of Products under Development for Hypoparathyroidism, H1 2018

Number of Products under Development by Companies, H1 2018

Products under Development by Companies, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Hypoparathyroidism - Pipeline by Ascendis Pharma A/S, H1 2018

Hypoparathyroidism - Pipeline by Chugai Pharmaceutical Co Ltd, H1 2018

Hypoparathyroidism - Pipeline by Eli Lilly and Co, H1 2018

Hypoparathyroidism - Pipeline by Entera Bio Ltd, H1 2018

Hypoparathyroidism - Pipeline by GC Pharma, H1 2018

Hypoparathyroidism - Pipeline by Shire Plc, H1 2018

Hypoparathyroidism - Dormant Projects, H1 2018

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License:
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Ascendis Pharma A/S

Chugai Pharmaceutical Co Ltd

Eli Lilly and Co

Entera Bio Ltd

GC Pharma

Shire Plc

Hypoparathyroidism Therapeutic Products under Development, Key Players in Hypoparathyroidism Therapeutics, Hypoparathyroidism Pipeline Overview, Hypoparathyroidism Pipeline, Hypoparathyroidism Pipeline Assessment


Related Products in vertical
red-whiteline

RECENT VIEWED REPORTS



Sign up for newsletter

Close
Apply For Job

  • Applicant Name
  • Job Function
  • Total Experience
  • Skills
  • Email ID
  • Notice Period
  • Current CTC & Expected CTC
  • Phone Number
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Your resume has been successfully received. HR will connect you within 14 days in case your resume gets shortlisted."
Close
Download Company Brochure

  • Name
  • Email
  • Company Name
  • Select Country*
  • Phone Number
  • Validation
  •   info-icon

    If validation code does not match, please refresh the page.

Close
Engage With Us

  • Name
  • Designation
  • Email
  • Phone No.
  • Company Name
  • Company URL
  • Select Country*
  • Requirements/ Comments
  • Validation
  • captcha  info-icon

    If validation code does not match, please refresh the page.

  • "Thanks for submitting the form. The concerned team will respond to your query in the next 8-12 hours"
Close

Compare

Expand